Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 3/20 | 0.36 |
| ▸ | GCKR | Q14397 | 3/20 | 0.36 |
| ▸ | MPL | P40238 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 12/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907441 | 0.75 | HSD11B1 (0.38) | MLYCDGCKGCKRHSD11B1 | |
| SCHEMBL2906900 | 0.75 | MYC (0.36) | MLYCDGCKGCKRHSD11B1 | |
| SCHEMBL2907382 | 0.74 | GCK (0.41) | MLYCDGCKGCKRHSD11B1 | |
| SCHEMBL2907239 | 0.71 | USP2 (0.52) | MLYCDGCKGCKRHSD11B1 | |
| SCHEMBL10165226 | 0.69 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL2906832 | 0.69 | MLYCD (0.37) | MLYCDGCKGCKRHSD11B1 | |
| SCHEMBL2907520 | 0.69 | MLYCD (0.37) | MLYCDGCKGCKRHSD11B1 | |
| SCHEMBL13210440 | 0.68 | MAPT (0.43) | MLYCDGCKGCKRHSD11B1 | |
| SCHEMBL2909131 | 0.68 | MLYCD (0.36) | MLYCDGCKGCKRHSD11B1HAO1 | |
| SCHEMBL19181908 | 0.68 | HSD11B1 (0.54) | GCKGCKRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735275-B1 | ARYL SULFONES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7754890-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | disclosed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1735275-A2 | ARYL SULFONES AND USES RELATED THERETO | Amgen Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005110980-A2 | ARYL SULFONES AND USES RELATED THERETO | AMGEN, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | ARSA, SULT2A1, UGT2B7 | MLYCD 1185/4885GCK 544/4885GCKR 512/4885 |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | HSD17B1, HSD3B1, HSD11B1 | MLYCD 482/4885GCK 277/4885GCKR 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.